At a glance
ClinicalIndex Comparison RecordN/ACompleted· 760 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Extended Spectrum Beta-lactamases - Treatment, Carriage, Environmental Dissemination And Population Epidemiology
In Brief
An observational study for Urinary Tract Infection and 2 related conditions. Completed, enrolled 760 participants.
Detailed Summary
This project aims at investigating the duration of human fecal carriage of bacteria harboring plasmid-borne resistance genes expressing Extended Spectrum beta-lactamases (ESBL), risk factors for infections with such bacteria and persistence, mobility and spread of ESBL in the environment and within households. It also aims to compare different methods of detecting ESBL carriage and treat patients with urinary tract infection caused by these bacteria.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Tract Infection, Infection Due to ESBL Bacteria, Environmental Contamination of ESBL
Countries--
CollaboratorsHelse Sor-Ost, University Hospital of North Norway, University of Oslo
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedApr 2013
Primary CompletionDec 2014
TodayJul 2026
First PostedApr 23, 2013
Enrollment StartFeb 1, 2009
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 13.2 years ago